Emergence client, Somru BioScience, “en Route to $7M Raise”: Entrevestor

August 14, 2018

To help launch its new products, Emergence client, Somru BioScience of Charlottetown, PEI, is raising a $7 million round of funding, and already has commitments for almost half this amount from government funders, writes Entrevestor.View the full story here!


Mohammed Moin: Somru’s VP of Business Development

During a presentation at the recent 2018 Atlantic Venture Forum, Somru Vice-President Mohammed Moin said the company has secured commitments worth $3.3 million in loans and grants from such bodies as the Atlantic Canada Opportunities Agency, the National Research Council’s IRAP program, Innovation P.E.I. and Skills P.E.I.

See also: Emergence client, Somru BioScience, receives $4M to research, develop affordable medicines

Somru is developing a range of products centred around antibody technology for research, diagnostic and clinical applications. Its aim is to create technological solutions to accelerate drug development. Moin shared updates on the life-science company during the Growth-Stage Company presentations at the AVF in Halifax.

We want to close [the funding round] by the end of this year,” he said in an interview. “There are some clients of ours that are also looking to invest but we have only just started that discussion about a month ago.”

Somru-Logo-low166The money will be used for research and development of some of Somru’s latest products. One development is IntelliB, a software solution that helps drug developers generate a fingerprint-like analysis of a novel drug to help copy it.

“We will fingerprint a biosimilar candidate and we’ll match it against the inventor’s drug using our algorithm, giving them the best candidate to go forward,” Moin told Entrevestor. “That way they won’t waste product where there is no chance to go forward. . . . It gives us a comprehensive solution for antibody development.”

The company is also developing a proprietary method for producing antibodies using chickens and their eggs rather than lab mice.

“With mice or rabbits, you have to sacrifice the animal,” said Moin. “It’s a more environmentally sustainable way of doing antibody development.”

Last September, Somru moved into a 5,000-square-foot office space in Charlottetown. Moin hopes to double his workforce by the end of the year, bringing the number of staff in its three Charlottetown facilities to around 40 people.

The company serves more than 70 clients scattered across 23 countries and is projected to rake in $1.5 million in revenue for the next fiscal year.

SOMRU3And, through a significant partnership that started in 2017 with Radiant Pharmaceuticals, a pharmaceutical company in Bangladesh, Somru predicts sales of $50 million over the next five years.

The company’s origins date back almost 15 years to when Moin moved to Canada from Bangladesh to study at the University of Prince Edward Island. His brother, Rafiq Islam, was attending university in Nebraska, where he was researching disease detection.

In 2012, they started Somru. And, because of its network of support for biotech companies, Charlottetown became the company’s headquarters.

Somru was one of six growth-stage companies to share their stories at the sixth annual AVF, along with Appili TherapeuticsBlueLight AnalyticsCeltxProcedureFlow and VineView.